Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023)
Summit Therapeutics (SMMT) reported Asset Writedowns and Impairment of $474000.0 for Q1 2023, down 94.4% quarter-over-quarter from $8.5 million in Q4 2022.
Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Summit Therapeutics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $474000.0 in Q1 2023.
- For the quarter ending Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $474000.0; the trailing twelve-month figure through Dec 2023 stood at $474000.0 (down 94.4% YoY), and the FY2023 full-year result was $474000.0, down 94.4% from the prior year.
- Asset Writedowns and Impairment for Q1 2023 stood at $474000.0, down from $8.5 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $8.5 million in Q4 2022, with the low at $474000.0 in Q1 2023.
- Historically, Asset Writedowns and Impairment has averaged $3.3 million across 3 years, with a median of $859000.0 in 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 474,000.00 |
| Mar 31, 2023 | 474,000.00 |
| Dec 31, 2022 | 8.47 Mn |
| Dec 31, 2022 | 8.47 Mn |
| Sep 30, 2020 | 859,000.00 |
| Sep 30, 2020 | 859,000.00 |